N-ФЕНИЛАРИЛСУЛЬФОНАМИД, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ УКЗАННОЕ СОЕДИНЕНИЕ В КАЧЕСТВЕ АКТИВНОГО ИНГРИДИЕНТА, СОЕДИНЕНИЕ, ЯВЛЯЮЩЕЕСЯ ПРОМЕЖУТОЧНЫМ В СИНТЕЗЕ УКАЗАННОГО СОЕДИНЕНИЯ, И СПОСОБ ЕГО ПОЛУЧЕНИЯ

摘要

(R<1> is COOH etc.; R<2> is hydrogen, methyl, etc.; R<3> and R<4> are a combination of methyl and methyl, etc.; R<5> is isopropyl etc.; Ar is thiazolyl, pyridyl, 5-methyl-2-furyl each optionally substituted with methyl; n is zero or 1), a synthetic intermediate for the compound and a process for its preparation. The compound of formula (I) binds to a prostaglandin E2 receptor, especially an EP1 subtype receptor, and antagonizes it. It is less affected by protein binding, so it has a satisfactory in vivo activity. Therefore, it is considered to be useful as an analgesic, an antipyretic agent, an agent for the treatment of pollakiuria (frequent urination) and/or lower urinary tract disease syndrome or an antineoplastic agent.